Inhibition of Na+,K+-ATPase by cisplatin and its recovery by 2-mercaptoethanol in human squamous cell carcinoma cells

Anti-Cancer Drugs

Volumn 10, Issue 2, 1999, Pages 203-211

  Sakakibara, Noriyuki ^a   Suzuki, Kuniaki ^a   Kaneta, Hiroyuki ^a   Yoshimura, Yoshitaka ^a   Deyama, Yoshiaki ^a   Matsumoto, Akira ^a   Fukuda, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Cisplatin; Na+,K+ ATPase; Nephrotoxicity; Oral squamous cell carcinoma; Thiol group

Indexed keywords

4 NITROPHENYL PHOSPHATE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; CISPLATIN; MERCAPTOETHANOL;

ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME INHIBITION; GINGIVA; HUMAN; HUMAN CELL; HYDROLYSIS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 0032999034     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199902000-00009     Document Type: Article

References (40)

1. Loehrer PJ and Einhorn LH. Drugs five years later. Cisplatin. Ann Intern Med 1984; 100: 704-13.
2. Rosenberg B. Cisplatin: its history and possible mechanisms of action. New York: Academic Press 1980: 9-10.
3. Zwelling LA and Kohn KW. Effects of cisplatin on DNA and the possible relationships to cytotoxicity and mutagenicity in mammalian cells. New York: Academic Press 1980: 21-35.
4. 2]. Science 1982; 218: 1075-82.
5. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5- fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167-72.
6. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923-5.
7. Guarino AM, Miller DS, Arnold ST, et al. Platinate toxicity: past, present, and prospects. Cancer Treat Rep 1979; 63: 1475-83.
8. Scanlon KJ, Safirstein RL, Thies H, Gross RB, Waxman S, Guttenplan JR. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res 1983; 43: 4211-5.
9. Mineura K, Sasajima T, Sasajima H, Kowada M. Inhibition of methionine uptake by cis-diamminedichloroplatinu-m(II) in experimental brain tumors. Int J Cancer 1996; 67: 681-3.
10. Esaki T, Nakano S, Tatsumoto T, et al. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 1992; 52: 6501-6.
11. Pratesi G, Gianni L, Manzotti C, Zunino F. Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 1988; 21: 237-40.
12. Ohmori T, Nishio K, Ohta S, et al. Ouabain-resistant non-small-cell lung-cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum(II) (CDDP). Int J Cancer 1994; 57: 111-6.
13. +-ATPase activity and cisplatin sensitivity between transformants induced by H-ras and those induced by K-ras. Int J Cancer 1994; 58: 672-7.
14. +-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res 1991; 51: 3677-81.
15. 2 receptor antago-nists in non-small-cell lung cancer cell lines. Br J Cancer 1996; 74: 1553-8.
16. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993; 67: 1171-6.
17. Tay LK, Bregman CL, Masters BA, Williams PD. Effects of cis-diamminedichloroplatinum(II) on rabbit kidney in vivo and on rabbit renal proximal tubule cells in culture. Cancer Res 1988; 48: 2538-43.
18. Nechay BR, Neldon SL. Characteristics of inhibition of human renal adenosine triphosphatases by cisplatin and chloroplatinic acid. Cancer Treat Rep 1984; 68: 1135-41.
19. Uozumi J, Litterst CL. The effect of cisplatin on renal ATPase activity in vivo and in vitro. Cancer Chemother Pharmacol 1985; 15: 93-6.
20. Daley-Yates PT, McBrien DC. The inhibition of renal ATPase by cisplatin and some biotransformation products. Chem-Biol Interact 1982; 40: 325-34.
21. Skou JC. The Na,K-pump. Methods Enzymol 1988; 156: 1-25.
22. +-ATPase. J Biol Chem 1994; 269: 19659-62.
23. Glynn IM, Karlish SJ. Occluded cations in active transport. Annu Rev Biochem 1990; 59: 171-205.
24. Post RL, Kume S, Tobin T, Orcutt B, Sen AK. Flexibility of an active center in sodium-plus-potassium adenosine triphosphatase. J Gen Physiol 1969; 54: 306s-26s.
25. +-ATPase: enzyme sources, preparative problems, and preparation from mammalian kidney. Methods Enzymol 1988; 156: 29-43.
26. Vasallo PM, Post RL. Calcium ion as a probe of the monovalent cation center of sodium, potassium ATPase. J Biol Chem 1986; 261: 16957-62.
27. Chifflet S, Torriglia A, Chiesa R, Tolosa S. A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases. Anal Biochem 1988; 168: 1-4.
28. Post RL, Hegyvary C, Kume S. Activation by adenosine triphosphate in the phosphorylation kinetics of sodium and potassium ion transport adenosine triphosphatase. J Biol Chem 1972; 247: 6530-40.
29. 32P-labeling of a (Na+K)-ATPase intermediate. Methods Enzymol 1967; 10: 773-6.
30. Suzuki K, Post RL. Equilibrium of phosphointermediates of sodium and potassium ion transport adenosine triphosphatase: action of sodium ion and Hofmeister effect. J Gen Physiol 1997; 109: 537-54.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-73.
32. Bodenner DL, Dedon PC, Keng PC, Borch RF. Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum (II)-induced cytotoxicity, DNA cross-linking, and gammaglutamyl transpeptidase inhibition. Cancer Res 1986; 46: 2745-50.
33. Pfeifle CE, Howell SB, Felthouse RD, et al. High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 1985; 3: 237-44.
34. Borch RF, Bodenner DL, Katz JC. Diethyldithiocarbamate and cis-patinum txicity. In: Plackes MP, Double EB, Krakoff IH, eds. Platinum cordination complexes in cancer chemotherapy. Dordrecht: Martinus Nijhoff 1984: 154-64.
35. Jones MM, Basinger MA, Holscher MA. Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity. Toxicology 1991; 68: 227-47.
36. Sadzuka Y, Shoji T, Takino Y. Mechanism of the increase in lipid peroxide induced by cisplatin in the kidneys of rats. Toxicol Lett 1992; 62: 293-300.
37. Naganuma A, Satoh M, Imura N. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice. Cancer Res 1987; 47: 983-7.
38. Satoh M, Aoki Y, Tohyama C. Protective role of metallothionein in renal toxicity of cisplatinum. Cancer Chemother Pharmacol 1997; 40: 358-62.
39. +)-ATPase from rectal glands of Squalus acanthias. Titrations and classification. Biochim Biophys Acta 1982; 688: 251-9.
40. +)-activated ATPase. XLVI. Effect of cation-induced conformational changes on sulfhydryl group modification. Biochim Biophys Acta 1980; 602: 144-54.